Table 1

Selected clinical trials targeting neoantigens as targets for personalised or off-the-shelf vaccines

StrategyClinicalTrials.gov identifierTumour typeSettingPhaseTreatmentTarget accrual
Personalised neoantigen vaccineNCT03558945Pancreatic tumourAdvancedPhase 1Personalised neoantigen vaccine60
NCT04087252Solid tumourAdvancedPhase 1Personalised neoantigen vaccine30
NCT03715985Melanoma, lung cancer, kidney cancerAdvancedPhase 1EVAX-01-CAF09b25
Personalised neoantigen vaccine with checkpoint inhibitorsNCT03606967Breast cancer (oestrogen receptor negative, HER2/Neu negative, triple-negative)AdvancedPhase 2Carboplatin, durvalumab gemcitabine, nab-paclitaxel, personalised synthetic long peptide vaccine, poly ICLC70
NCT02950766Kidney cancerAdvancedPhase 1NeoVax, Ipilimumab15
NCT03359239Urothelial, bladder cancerAdvancedPhase 1Atezolizumab, PGV001, Poly ICLC15
NCT02287428GlioblastomaAdvancedPhase 1Radiation Therapy, personalised neoantigen vaccine, pembrolizumab46
NCT03289962Melanoma, lung cancer, bladder cancer, colorectal cancer, triple negative breast cancer, renal cancer, head and neck cancer, other solid cancersAdvancedPhase 1RO7198457/mRNA+atezolizumab770
NCT03532217Prostate cancerAdvancedPhase 1PROSTVAC-V, PROSTVAC-F, Nivolumab, Ipilimumab, Neoantigen DNA vaccine20
NCT03639714Lung cancer, microsatellite stable colorectal cancer, gastro-oesophageal adenocarcinoma, urothelial carcinomaAdvancedPhase 1/2GRT-C901/GRT-R902 +nivolumab/ipilimumab241
NCT02897765Melanoma, lung cancer, bladder cancerAdvancedPhase 1bNEO-PV-01+nivolumab55
Off-the-shelf neoantigen vaccineNCT03391232Colorectal cancerAdvancedPhase 1/2PolyPEPI1018 colorectal cancer vaccine15
Off-the-shelf neoantigen vaccine with checkpoint inhibitorsNCT03953235Lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumoursAdvancedPhase 1/2A fixed set of neoantigens that are shared across a subset of cancer patients+nivolumab144
NCT04041310Mismatch repair deficient or microsatellite instability high colorectal cancer, gastric, gastro-oesophageal junction and endometrial tumoursAdvancedPhase 1Nous-209 (FrameShift Peptides neoantigen-encoding genetic vaccines)+pembrolizumab34
NCT03893903GliomaAdvancedPhase 13 arms: IDH1R132H peptide vaccine, IDH1R132H peptide vaccine and avelumab, avelumab alone.60
  • IDH, isocitrate dehydrogenase; Poly ICLC, Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose.